The firm is developing and beta-testing a line of guide RNA libraries to support CRISPR-based targeted capture and sequencing approaches.
The firm is seeking damages and various injunctions, citing 11 different counts of fraud, breach of contract, tortious interference, and unfair competition.
The funding is being provided to a number of early-career investigators and collaborative research groups using genomics and other technologies.
The researchers reported that targeting HDAC4 in the patient-derived neurons appeared to correct the expression of genes that differed in the disease state.
In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.
The group aims to collect and sequence more than 2,500 blood samples by 2020 to improve primary diagnosis and treatment options for patients suffering from Parkinson's disease.
According to the researchers, led by a team at the University of Cambridge, detecting somatic brain mutations in patients during their life may increase diagnostic precision and lead to new therapies.
Centogene will collect dried blood spot samples and perform genetic analysis to find and recruit Parkinson's disease patients for Denali's LRRK2 inhibitor trials.
Scientific American reports that drugs being pursued to treat small fraction of Parkinson's disease patients with a certain gene mutation could also help a larger portion of patients.
Researchers in Japan being a new trial of induced pluripotent stem cells to treat Parkinson's disease, Science reports.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.